Beta Drugs Limited — Board Meeting, 15-05-2025: Outcome of Board Meeting

Beta Drugs has announced a board meeting that approved the financial results for the quarter and half-year. Consolidated revenue grew 24% YoY to Rs 368.8 Cr, driven by a 25% jump in Own Brands and 73% surge in exports. EBITDA stood at Rs 81 Cr with a 22.4% margin, while net profit before exceptional items increased 26% to Rs 45.8 Cr. Beta remains net debt-free with a Rs 14.3 Cr cash surplus. With new global approvals and a focus on oncology, the company targets Rs 450 Cr revenue in FY26 and aims to double its topline in three years.